Company Profile For Shire Plc

Shire plc, formerly Shire Ltd. is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), and gastrointestinal (GI) diseases, as well as opportunities in other therapeutic areas. Substantially all of the Company’s revenues and net assets are attributable to the research and development (R&D), manufacture, sale and distribution of pharmaceutical products within two operating segments: Specialty Pharmaceuticals and HGT. The Company’s key marketed products as of December 31, 2008, include VYVANSE; DAYTRANA; ADDERALL XR; PENTASA; LIALDA/ MEZAVANT; FOSRENOL; CALCICHEW; CARBATROL; REMINYL/REMINYL XL; XAGRID; REPLAGAL; ELAPRASE, and FIRAZYR.

BRIEF: For the nine months ended 30 September 2009, Shire Plc.'srevenues decreased 6% to $2.11B. Net income from continuing operations totaled $329.7M, up from $15.6M. Revenues reflect a decrease in income from Product sales, Royalties. Net income reflects lower cost of sales, a decrease in selling, general & administrative expenses, the absence of in-process R&D charge and an improved operating income.